摘要
目的:探讨索拉非尼联合小剂量阿糖胞苷治疗FLT3^+复发难治性急性髓系白血病的安全性和有效性。方法:应用索拉非尼联合小剂量阿糖胞苷治疗7例FLT3^+复发难治性急性髓系白血病患者,并观察其疗效和不良反应。结果:经治疗后7例FLT3^+复发难治性急性髓系白血病患者中5例达完全血液学缓解(complete remission,CR),2例达部分血液学缓解(partial remission,PR),总有效率(overall remission rate,ORR)为100%。7例均未发生严重出血、恶心和呕吐等不良反应。结论:索拉非尼联合小剂量阿糖胞苷可以诱导复发难治性FLT3^+急性髓系白血病的缓解并具有一定疗效,因此值得进一步对其研究和观察。
Objective:To study the efficacy and safety of sorafenib combined with low dose cytarabine for treating patients with FLT3^+ relapsed and refractory acute myeloid leukemia(FLT3^+ RR-AML).Methods:Seven patients with FLT3^+ RR-AML were treated with sorafenib and low dose cytarabine.The curative rate and adverse effects were observed in these patients.Results:Out of 7 RR-AML patients after treatment,5 patients achieved complete remission(CR),2patients achieved partial remission(PR),and the overall response rate(ORR) after one course of therapy was 100%.No severe bleeding,nausea,vomiting and other side effects were found in these patients.Conclusion:Sorafenib combined with low dose cytarabine can effectively induce the remission of FLT3^+ RR-AML patients,and is worth for further clinical trails to verify its safty and efficiency.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2016年第2期394-398,共5页
Journal of Experimental Hematology
